Federated Hermes Inc. Reduces Position in United Therapeutics Corporation (NASDAQ:UTHR)

Federated Hermes Inc. lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 33.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,716 shares of the biotechnology company’s stock after selling 2,362 shares during the quarter. Federated Hermes Inc.’s holdings in United Therapeutics were worth $1,454,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of UTHR. FMR LLC grew its position in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of United Therapeutics during the 1st quarter valued at $101,354,000. GAMMA Investing LLC lifted its holdings in shares of United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock worth $68,422,000 after acquiring an additional 221,202 shares during the last quarter. Northern Trust Corp raised its position in United Therapeutics by 29.1% during the fourth quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company’s stock valued at $172,487,000 after purchasing an additional 110,298 shares in the last quarter. Finally, AustralianSuper Pty Ltd lifted its stake in United Therapeutics by 49.0% during the first quarter. AustralianSuper Pty Ltd now owns 282,739 shares of the biotechnology company’s stock worth $87,160,000 after purchasing an additional 92,959 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on UTHR shares. Wells Fargo & Company dropped their target price on United Therapeutics from $314.00 to $295.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Morgan Stanley cut their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald initiated coverage on United Therapeutics in a report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price objective for the company. Finally, Bank of America dropped their target price on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research report on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $379.69.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $302.41 on Thursday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The business has a fifty day moving average price of $297.36 and a 200-day moving average price of $312.30. The firm has a market capitalization of $13.64 billion, a price-to-earnings ratio of 11.80, a price-to-earnings-growth ratio of 4.62 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter in the previous year, the company earned $5.85 EPS. The business’s quarterly revenue was up 11.7% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total value of $3,345,210.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,185,469.91. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 70,681 shares of company stock worth $21,318,359 in the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.